In hepatocellular carcinoma downregulation of PDK4 is associated with poor prognosis (26), and PDK4 downregulation in lung cancer promoted cell proliferation and tumor growth (27), while high PDK4 expression was correlated with poor patient outcome in breast cancer (28). Here, PDK4 is linked to lung cancer.